) while maintaining reduced toxicity toward MRC-5 normal fibroblasts, resulting in a markedly improved selectivity index. Overall, this work demonstrates that RGD-functionalized nZIF-8 is a promising pH-responsive and selective nanoplatform for the targeted delivery of repurposed therapeutics in breast cancer treatment.
No takes yet. Share an insight, caveat, or question.
Silvaraju et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: